Palisade Bio, Inc. (PALI)

Palisade Bio Statistics

Total Valuation

Palisade Bio has a market cap or net worth of $331.77 million. The enterprise value is $198.46 million.

Market Cap	331.77M
Enterprise Value	198.46M

Important Dates

The next estimated earnings date is Monday, May 11, 2026, after market close.

Earnings Date	May 11, 2026
Ex-Dividend Date	n/a

Share Statistics

Palisade Bio has 165.88 million shares outstanding. The number of shares has increased by 3,830.18% in one year.

Current Share Class	165.88M
Shares Outstanding	165.88M
Shares Change (YoY)	+3,830.18%
Shares Change (QoQ)	+2,650.55%
Owned by Insiders (%)	0.03%
Owned by Institutions (%)	57.73%
Float	122.27M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	2.46
P/TBV Ratio	2.56
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 28.95, with a Debt / Equity ratio of 0.00.

Current Ratio	28.95
Quick Ratio	28.83
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-1,805.60

Financial Efficiency

Return on equity (ROE) is -24.52% and return on invested capital (ROIC) is -16.46%.

Return on Equity (ROE)	-24.52%
Return on Assets (ROA)	-15.54%
Return on Invested Capital (ROIC)	-16.46%
Return on Capital Employed (ROCE)	-13.92%
Weighted Average Cost of Capital (WACC)	12.80%
Revenue Per Employee	n/a
Profits Per Employee	-$2.10M
Employee Count	8
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +187.77% in the last 52 weeks. The beta is 1.56, so Palisade Bio's price volatility has been higher than the market average.

Beta (5Y)	1.56
52-Week Price Change	+187.77%
50-Day Moving Average	1.79
200-Day Moving Average	1.45
Relative Strength Index (RSI)	57.56
Average Volume (20 Days)	3,173,151

Short Selling Information

The latest short interest is 26.15 million, so 15.77% of the outstanding shares have been sold short.

Short Interest	26.15M
Short Previous Month	26.73M
Short % of Shares Out	15.77%
Short % of Float	21.39%
Short Ratio (days to cover)	7.59

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-18.06M
Pretax Income	-16.78M
Net Income	-16.78M
EBITDA	-18.05M
EBIT	-18.06M
Earnings Per Share (EPS)	-$0.30

Balance Sheet

The company has $133.39 million in cash and $71,000 in debt, with a net cash position of $133.31 million or $0.80 per share.

Cash & Cash Equivalents	133.39M
Total Debt	71,000
Net Cash	133.31M
Net Cash Per Share	$0.80
Equity (Book Value)	129.38M
Book Value Per Share	0.81
Working Capital	129.59M

Cash Flow

Operating Cash Flow	-10.85M
Capital Expenditures	n/a
Depreciation & Amortization	3,000
Net Borrowing	-320,000
Free Cash Flow	-10.85M
FCF Per Share	-$0.07

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Palisade Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3,830.18%
Shareholder Yield	-3,830.18%
Earnings Yield	-5.06%
FCF Yield	-3.27%

Analyst Forecast

The average price target for Palisade Bio is $12.00, which is 500.00% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$12.00
Price Target Difference	500.00%
Analyst Consensus	Strong Buy
Analyst Count	6
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-32.15%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on April 8, 2024. It was a reverse split with a ratio of 1:15.

Last Split Date	Apr 8, 2024
Split Type	Reverse
Split Ratio	1:15

Scores

Altman Z-Score	n/a
Piotroski F-Score	2